E-LIB Suche - Ergebnisse für: Bahlis, N.

1

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRM..:

Donk, NWCJV ; Popat, R ; Rosiol, L...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S397-S398 , 2023

Link: https://doi.org/10.1016/..

2

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSE..:

Nooka, A ; Lesokhin, A ; Mohty, M...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S405 , 2023

Link: https://doi.org/10.1016/..

3

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANT..:

Mohty, M ; Tomasson, M ; Arnulf, B...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S404-S405 , 2023

Link: https://doi.org/10.1016/..

4

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N. ; Cortes-Selva, D. ; Casneuf, T....
HemaSphere. 7 (2023) S2 - p. 28-29 , 2023

Link: https://doi.org/10.1097/..

5

CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC)..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S31 , 2023

Link: https://doi.org/10.1016/..

6

P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) ..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S5-S6 , 2023

Link: https://doi.org/10.1016/..

7

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATI..:

Rodríguez-Otero, P. ; Ailawadhi, S. ; Arnulf, B....
HemaSphere. 7 (2023) S2 - p. 7-8 , 2023

Link: https://doi.org/10.1097/..

8

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INE..:

Facon, T. ; Plesner, T. ; Usmani, S....
HemaSphere. 7 (2023) S2 - p. 18-19 , 2023

Link: https://doi.org/10.1097/..

9

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere. 7 (2023) S2 - p. 14-15 , 2023

Link: https://doi.org/10.1097/..

10

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUM..:

Mateos, M ; Hari, P ; Bahlis, N...
HemaSphere. 6 (2022) - p. 9-9 , 2022

Link: https://doi.org/10.1097/..

11

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMA..:

Mateos, M. V. ; Bahlis, N. ; Costa, L....
HemaSphere. 6 (2022) - p. 1891-1892 , 2022

Link: https://doi.org/10.1097/..

12

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF ..:

van de Donk, N. W. ; Bahlis, N. ; Mateos, M.-V....
HemaSphere. 6 (2022) - p. 84-85 , 2022

Link: https://doi.org/10.1097/..

13

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELR..:

Dalovisio, A. ; Bahlis, N. ; Raje, N....
HemaSphere. 6 (2022) - p. 788-789 , 2022

Link: https://doi.org/10.1097/..

14

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-..:

Popat, R. ; Moreau, P. ; Usmani, S. Z....
HemaSphere. 6 (2022) - p. 812-813 , 2022

Link: https://doi.org/10.1097/..

15

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT..:

Köse, M. C. ; Bergiers, I. ; Malfait, M....
HemaSphere. 6 (2022) - p. 71-72 , 2022

Link: https://doi.org/10.1097/..